Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
A Single-arm, Open-label, Phase I Clinical Study of Blinatumomab Combined With Low-dose DLI as Maintenance Therapy After Transplantation for B-ALL
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Lu Wang
- Telefonnummer: 86-10-66937079
- E-mail: wangludophine@163.com
Undersøgelse Kontakt Backup
- Navn: Liping Dou, Dr.
- E-mail: lipingruirui@163.com
Studiesteder
-
-
-
Beijing, Kina
- Rekruttering
- Chinese PLA General Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
1) Voluntary participation: The participant or legal guardian fully understands this clinical study, provides informed consent (ICF), and is willing/able to comply with all trial procedures.
2) Age: <70 years old at screening, any gender. 3) Diagnosis: High-risk acute B-lymphoblastic leukemia (B-ALL) with MRD-negative status post-transplant. High-risk factors include:
- >CR1 status
- Pre-transplant MRD+ status
- Ph-like subtype
- KMT2A rearrangement
Other high-risk cytogenetic/genetic factors per ELN 2023 criteria. 4) Allergy: No history of severe allergies. 5) Liver function: ALT and AST ≤ 2.5 × ULN; Total bilirubin ≤ 2 × ULN. 6) Renal function: Serum creatinine ≤ ULN. 7) Other conditions: Absence of uncontrolled infections or severe psychiatric disorders.
8) Performance status: ECOG score 0-3, with life expectancy ≥ 4 months. 9) MRD status: Bone marrow flow cytometry confirmed MRD-negative before enrollment.
10) Engraftment: Evidence of myeloid and platelet engraftment. 11) GVHD: No active graft-versus-host disease (GVHD).
Exclusion Criteria:
1) Drug hypersensitivity/contraindications: Patients with known allergies or contraindications to the investigational drug(s).
2) Pregnancy/lactation: Pregnant or breastfeeding female patients. 3) Active infection/GVHD: Patients with active infection or active graft-versus-host disease (GVHD).
4) Substance abuse: Patients with chronic heavy smoking or alcohol use that may interfere with clinical evaluation.
5) Impaired consent/compliance: Patients unable to provide informed consent or comply with procedures due to psychiatric/neurological disorders.
6) Recent major surgery: Patients who underwent major organ surgery within the past 6 weeks.
7) Organ dysfunction:
- Liver: ALT or AST > 2.5 × ULN; Total bilirubin > 2 × ULN
- Kidney: Serum creatinine > ULN 8) Investigator judgment: Patients deemed ineligible by investigators (e.g., poor compliance, substance abuse).
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: BLINA+DLI
blinatumomab 9ug d1-7, 28ug d8-14, DLI ( CD3+cell 1×10^5/kg)
|
blinatumomab 9ug d1-7, 28ug d8-14
CD3+cell 1×10^5/kg
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
1 year progression-free-survival
Tidsramme: 1 year
|
the percentage of patients who remain alive and whose disease has not gotten relapse one full year after they started treatment.
|
1 year
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
1 year aGVHD rate
Tidsramme: 100 days after transplantation
|
Number of participants with aGVHD as assessed by acute graft versus host disease grading criteria (refer to Glucksberg criteria) The cumulative incidences of aGvHD was defined as the number and the ratio of the participants with aGVHD.
|
100 days after transplantation
|
|
1 year cGVHD rate
Tidsramme: 365 days after transplantation
|
Number of participants with cGVHD as assessed by chronic graft versus host disease grading criteria (refer to NIH criteria) cGvHD was diagnosed and graded according to the 2014 National Institutes of Health (NIH) consensus criteria: mild, moderate or severe respectively.
|
365 days after transplantation
|
|
Nonrelapse mortality (NRM)
Tidsramme: 365 days after transplantation
|
Defined as the proportion of subjects who died due to causes other than malignancy relapse
|
365 days after transplantation
|
|
Overall survival (OS)
Tidsramme: 365 days after transplantation
|
Defined as the time from study enrollment (first day of ruxolitinib treatment) to death due to any cause
|
365 days after transplantation
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- BLINADLISTUDY
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .